Newsgroup: it.economia.borsa
Titolo: cell conference di ieri

Mr. Bianco ieri in conferenza ha detto:
Nessun problema nel braccio dello Xiotax le anomalie erano in quello del
Taxol
fra una 1à settimana si avrà il responso di uno studio fra la correlazione
tra estrogeni e Xiotax
fra 6 mesi si avrà un primo responso con valenza statistica sul PIONEER su
200 pazienti che mostrerà l'efficacia dello Xiotax su donne con estrogeni a
livelli normali l'interim invece andrà com'è ormai noto al 1 sem 2008
in un periodo di tempo fra i 30 ed i 60 giorni riprenderanno gli
arruolamenti..che erano stati sospesi

adesso ti dico la mia
senza fare lo spiritoso
1) ha 3 gap aperti  1,3  circa 1,43  1,78
2) uno da 7 a 4
il resto non lo leggo nemmeno credimi è solo
una girandola  di notizie inutili.
facendo delle ricerche approfondite
su un titolo mi sono imbattuto su
notizie che all'estero alcuni hanno
diffuso ma che la massa non ha letto.
qui si vive di redazionali 

 senza fare lo spiritoso





giapponesi???
-- 
questo articolo e` stato inviato via web dal servizio gratuito 
http://www.newsland.it/news
 segnala gli abusi ad 
ab...@newsland.it

 ha scritto nel messaggio
news:4551a8e2$0$13764$4faf...@reader3.news.tin.it...

mah io entro natale liquido mia posizione media 1.33 qualsiasi prezzo sia
speriamo in buone news altrimenti si ritorna sotto 1!!!!

      New Research Identifies Unique Estrogen Augmented Mechanism for
Enhanced Efficacy of XYOTAX(TM) in Women
Four Presentations at 18th Annual EORTC-NCI-AACR Meeting Underscores
Potential
                    for Biologically Enhanced ChemotherapyPRAGUE, Nov. 8
/PRNewswire-FirstCall/ -- At the 18th Annual meeting of the European
Organization for Research and Treatment of Cancers, National Cancer
Institute and American Association for Cancer Research (EORTC-NCI-AACR),
Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTAX: CTIC) scientists
presented new data showing the influence of estrogen on the antitumor
efficacy, biodistribution, uptake, and metabolism of XYOTAX(TM) (paclitaxel
poliglumex, PPX) and subsequent intracellular release of free paclitaxel.
The presentations summarized a gender-specific analysis of STELLAR 3 and 4
lung cancer clinical trial data and presented new preclinical data. The
preclinical data show that in the presence of estrogen tumor growth is
enhanced and the activity of an enzyme that metabolizes XYOTAX, cathepsin B,
is increased, resulting in a doubling of anti-tumor activity. In addition,
the preclinical data confirms the preferential distribution of XYOTAX to
tumor tissue and demonstrates the uptake of XYOTAX by endosomes and release
of the free paclitaxel from the XYOTAX conjugate by lysosomal enzymes.
      "The preclinical data, presented for the first time at a peer-reviewed
meeting, provide the scientific basis for the clinical observation that
women treated with XYOTAX, and in particular women with normal estrogen
levels, have superior survival over women who were randomized to standard
chemotherapy in the STELLAR clinical trials," noted Jack W. Singer, M.D.,
Chief Medical Officer at CTI. "XYOTAX is currently being studied in a phase
III trial, known as the PIONEER trial, in women with advanced lung cancer to
validate the earlier clinical results.
      "XYOTAX is taken up by the cells through endocytosis and metabolized
within the cell to release the active chemotherapy, resulting in a
'biologically enhanced paclitaxel.' The augmentation of the effect of XYOTAX
in the presence of the estrogen beta receptor may open a whole new era of
gender-specific individualized medicine," Singer added.
      "The preclinical studies demonstrate in tumor cells, in cultures, and
in animal models that XYOTAX is actively taken up by tumor cells and
metabolized within tumor tissue to release free paclitaxel. The studies
demonstrate that estrogen substantially promotes the rate of growth of lung
cancer and colon cancer cells in immunodeficient mice," said Gabriella
Pezzoni, Ph.D., Scientific Senior Director of Cell Therapeutics Europe
S.r.l. (CTI-Europe). "Although estrogen has no influence on the efficacy of
standard paclitaxel, estrogen enhances the efficacy of XYOTAX in animal
models, probably by increasing the activity of its key metabolizing enzyme,
cathepsin B."
      Effect of Estrogen on Cathepsin B Activity and Antitumor Efficacy of
Paclitaxel Poliglumex in human tumor Xenografts (Abstract #633)
      In a poster presentation, Stefano Di Giovine, Ph.D., Pharmacology
Manager of CTI-Europe presented data on the effect of circulating estrogen
levels on tumor growth and levels of cathepsin B in tumor tissue. The study
showed that when additional estrogen was given, it substantially increased
the tumor growth rate in colon cancer (HT-29) and NSCLC (H460) models. In
addition, cathepsin B activity in the tumors increased by 35 to 40 percent
in the presence of estrogen. The study also found that in estradiol
supplemented female mice, XYOTAX demonstrated a nearly two-fold increase in
anti-tumor activity compared to non-supplemented animals in the colon cancer
tumor model. Studies are ongoing to evaluate the effect of estrogen on
XYOTAX activity in the non-small cell lung tumor model.
      Energy Dependent Uptake of Paclitaxel Poliglumex by Human NSCLC Tumor
Murine Macrophase-like Cell Lines (Abstract #643)
      Using a monoclonal antibody that specifically recognizes XYOTAX,
Stewart Chipman, Ph.D., Vice President of Research Programs at CTI,
presented data showing that XYOTAX is taken up in macrophages and NSCLC
tumor cells by energy-dependent endocytosis into endosomes. The endosomes
then fuse with lysosomes, exposing XYOTAX to lysosomal enzymes, principally
cathepsin B, that metabolize the drug to release free paclitaxel.
      Paclitaxel Poliglumex Cellular Uptake by Normal Tissues and Human
Tumor Xenograft: an IHC Study in Nude Mice (Abstract #637)
      In a poster presentation, Massenzio Fornasier, Toxicology Associate
Director of CTI-Europe presented data using the anti-XYOTAX monoclonal
antibody to demonstrate localization at the cellular level of XYOTAX in
tumor bearing mice. The studies confirmed the preferential distribution of
XYOTAX to tumor tissue likely through the enhanced permeability and
retention (EPR) with accumulation in perinecrotic zones. XYOTAX also
localized in tissue-associated macrophages to tumor and in
reticuloendothelial tissues, such as the liver, spleen, and lung.
      Effect of Gender on Outcome in Two Randomized Phase III Trials of
Paclitaxel Poliglumes (PPX) in Chemo-Naïve Patients with Advanced NSCLC and
Poor Performance Status (PS) (Abstract #645)
      The efficacy of XYOTAX as a first-line treatment in advanced NSCLC was
evaluated in two randomized phase III trials, known as STELLAR 3 and 4, in a
total of 781 patients. In a poster presentation by Dr. Singer a hypothesis
generating composite analysis of the two studies was presented. The
composite analysis was performed because each study individually had limited
statistical power for a gender-specific analysis and because the concurrent
studies had identical inclusion and exclusion criteria and stratifications
and similar demographics. The composite analysis showed a statistically
significant survival benefit for women receiving XYOTAX compared to the
control arms whereas men treated with XYOTAX did similarly to men treated
with comparator agents. The largest improvement in survival with XYOTAX was
seen in women under age 55 and in women with pre-menopausal estrogen levels,
regardless of age.
      About the PIONEER Clinical Trial
      The PIONEER clinical trial is targeting approximately 170 sites in
North and South America, Europe, and Asia. The trial was originally designed
to enroll approximately 600 PS2 chemotherapy-naïve women with advanced stage
NSCLC. Each study arm will be randomized to receive either XYOTAX (at a dose
of 175mg/m2 paclitaxel equivalents) or paclitaxel (at a dose of 175mg/m2)
once every three weeks. The primary endpoint is superior overall survival
with several secondary endpoints including disease control, response rate in
patients with measurable disease, time to disease progression, and
disease-related symptoms. For more information on the PIONEER trial, call
1-800-715-0944
.
      About XYOTAX
      XYOTAX(TM) (paclitaxel poliglumex) is a biologically-enhanced
chemotherapeutic that links paclitaxel, the active ingredient in Taxol(R),
to a biodegradable polyglutamate polymer, which results in a new chemical
entity. When bound to the polymer, the chemotherapy is rendered inactive,
potentially sparing normal tissue's exposure to high levels of unbound,
active chemotherapy and its associated toxicities. Blood vessels in tumor
tissue, unlike blood vessels in normal tissue, are porous to molecules like
polyglutamate. Based on preclinical studies, it appears that XYOTAX is
preferentially distributed to tumors due to their leaky blood vessels and
trapped in the tumor bed allowing significantly more of the dose of
chemotherapy to localize in the tumor than with standard paclitaxel. Once
inside the tumor cell, enzymes metabolize the protein polymer, releasing the
paclitaxel chemotherapy. Preclinical and clinical studies support that
XYOTAX metabolism by lung cancer cells may be influenced by estrogen, which
could lead to enhanced release of paclitaxel and efficacy in women with lung
cancer compared to standard therapies.